Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand

• Zimmer now anticipates full-year adjusted earnings of $8.47 to $8.59 per share, up from its previous forecast of $8.40 to $8.55. Analysts expects around $8.48 per share, according to LSEG data.
• The company posted second-quarter revenue of $2.18 billion, up 4.8% from a year earlier, beating the $2.13 billion analysts had expected. Adjusted earnings were $2.07 per share, topping estimates of $2.01.

Aug. 5 (Reuters) - Zimmer Biomet on Wednesday reported better-than-expected quarterly profit and sales and raised its full-year profit forecast, as demand for its devices used in orthopedic procedures stayed strong.

Shares of the Warsaw, Indiana-based company rose over 5% in premarket trading.

• The medical device maker is in midst of a transition to a more dedicated and specialized U.S. sales channel, aiming to complete the majority of this transition by the end of 2027.
• Revenue from the U.S., which represented about 58% of Zimmer's total net sales in 2025, rose 5.6% to $1.24 billion in the quarter ended June 30.
• "We delivered strong second-quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation," said chief executive Ivan Tornos.
• Revenue from the hips business rose 5% to $562.7 million, while the knee business generated $828.9 million, up a modest 0.4%.
• The unit that sells products for sports injuries and fractures increased 6.4% to $586 million.